खोज परिणाम - Morales, Serafín

  • प्रदर्शित 1 - 20 परिणाम 20
परिणाम को परिष्कृत करें
  1. 1
    Her2-Positive Cancers and Antibody-Based Treatment: State of the Art and Future Developments

    Her2-Positive Cancers and Antibody-Based Treatment: State of the Art and Future Developments द्वारा Morales, Serafin, Gasol, Ariadna, Sanchez, Douglas Rene

    प्रकाशित 2021
    पूर्ण पाठ प्राप्त करें पूर्ण पाठ प्राप्त करें पूर्ण पाठ प्राप्त करें
    मूलपाठ
    सूची में सहेजें
    में बचाया:
  2. 2
    Phase I/II study to assess the clinical pharmacology and safety of single ascending and multiple subcutaneous doses of PF-06881894 in women with non-distantly metastatic breast cancer

    Phase I/II study to assess the clinical pharmacology and safety of single ascending and multiple subcutaneous doses of PF-06881894 in women with non-distantly metastatic breast can... द्वारा Yao, Hsuan-Ming, Jones, Sarah Ruta, Morales, Serafin, Moosavi, Shahrzad, Zhang, Jeffrey, Freyman, Amy, Ottery, Faith D.

    प्रकाशित 2021
    पूर्ण पाठ प्राप्त करें पूर्ण पाठ प्राप्त करें पूर्ण पाठ प्राप्त करें
    मूलपाठ
    सूची में सहेजें
    में बचाया:
  3. 3
    Are Transcription Factors Plausible Oncotargets for Triple Negative Breast Cancers?

    Are Transcription Factors Plausible Oncotargets for Triple Negative Breast Cancers? द्वारा Marqués, Marta, Sorolla, Maria Alba, Urdanibia, Izaskun, Parisi, Eva, Hidalgo, Iván, Morales, Serafín, Salud, Antonieta, Sorolla, Anabel

    प्रकाशित 2022
    पूर्ण पाठ प्राप्त करें पूर्ण पाठ प्राप्त करें पूर्ण पाठ प्राप्त करें
    मूलपाठ
    सूची में सहेजें
    में बचाया:
  4. 4
    Long-Term Cardiac Safety and Survival Outcomes of Neoadjuvant Pegylated Liposomal Doxorubicin in Elderly Patients or Prone to Cardiotoxicity and Triple Negative Breast Cancer. Final Results of the Multicentre Phase II CAPRICE Study

    Long-Term Cardiac Safety and Survival Outcomes of Neoadjuvant Pegylated Liposomal Doxorubicin in Elderly Patients or Prone to Cardiotoxicity and Triple Negative Breast Cancer. Fina... द्वारा Gil-Gil, Miguel J., Bellet, Meritxell, Bergamino, Milana, Morales, Serafín, Barnadas, Agustí, Manso, Luís, Saura, Cristina, Fernández-Ortega, Adela, Garcia-Martinez, Elena, Martinez-Jañez, Noelia, Melé, Mireia, Villagrasa, Patricia, Celiz, Pamela, Perez Martin, X., Ciruelos, Eva, Pernas, Sonia

    प्रकाशित 2021
    पूर्ण पाठ प्राप्त करें पूर्ण पाठ प्राप्त करें पूर्ण पाठ प्राप्त करें
    मूलपाठ
    सूची में सहेजें
    में बचाया:
  5. 5
    Neoadjuvant eribulin in HER2-negative early-stage breast cancer (SOLTI-1007-NeoEribulin): a multicenter, two-cohort, non-randomized phase II trial

    Neoadjuvant eribulin in HER2-negative early-stage breast cancer (SOLTI-1007-NeoEribulin): a multicenter, two-cohort, non-randomized phase II trial द्वारा Pascual, Tomás, Oliveira, Mafalda, Villagrasa, Patricia, Ortega, Vanesa, Paré, Laia, Bermejo, Begoña, Morales, Serafín, Amillano, Kepa, López, Rafael, Galván, Patricia, Canes, Jordi, Salvador, Fernando, Nuciforo, Paolo, Rubio, Isabel T., Llombart-Cussac, Antonio, Di Cosimo, Serena, Baselga, José, Harbeck, Nadia, Prat, Aleix, Cortés, Javier

    प्रकाशित 2021
    पूर्ण पाठ प्राप्त करें पूर्ण पाठ प्राप्त करें पूर्ण पाठ प्राप्त करें
    मूलपाठ
    सूची में सहेजें
    में बचाया:
  6. 6
    A phase II study of combined ridaforolimus and dalotuzumab compared with exemestane in patients with estrogen receptor-positive breast cancer

    A phase II study of combined ridaforolimus and dalotuzumab compared with exemestane in patients with estrogen receptor-positive breast cancer द्वारा Baselga, José, Morales, Serafin M., Awada, Ahmad, Blum, Joanne L., Tan, Antoinette R., Ewertz, Marianne, Cortes, Javier, Moy, Beverly, Ruddy, Kathryn J., Haddad, Tufia, Ciruelos, Eva M., Vuylsteke, Peter, Ebbinghaus, Scot, Im, Ellie, Eaton, Lamar, Pathiraja, Kumudu, Gause, Christine, Mauro, David, Jones, Mary Beth, Rugo, Hope S.

    प्रकाशित 2017
    पूर्ण पाठ प्राप्त करें पूर्ण पाठ प्राप्त करें पूर्ण पाठ प्राप्त करें
    मूलपाठ
    सूची में सहेजें
    में बचाया:
  7. 7
    A randomized phase II trial of ridaforolimus, dalotuzumab, and exemestane compared with ridaforolimus and exemestane in patients with advanced breast cancer

    A randomized phase II trial of ridaforolimus, dalotuzumab, and exemestane compared with ridaforolimus and exemestane in patients with advanced breast cancer द्वारा Rugo, Hope S., Trédan, Olivier, Ro, Jungsil, Morales, Serafin M., Campone, Mario, Musolino, Antonino, Afonso, Noémia, Ferreira, Marta, Park, Kyong Hwa, Cortes, Javier, Tan, Antoinette R., Blum, Joanne L., Eaton, Lamar, Gause, Christine K., Wang, Zhen, Im, Ellie, Mauro, David J., Jones, Mary Beth, Denker, Andrew, Baselga, José

    प्रकाशित 2017
    पूर्ण पाठ प्राप्त करें पूर्ण पाठ प्राप्त करें पूर्ण पाठ प्राप्त करें
    मूलपाठ
    सूची में सहेजें
    में बचाया:
  8. 8
    Comparing Neoadjuvant Nab-paclitaxel vs Paclitaxel Both Followed by Anthracycline Regimens in Women With ERBB2/HER2-Negative Breast Cancer—The Evaluating Treatment With Neoadjuvant Abraxane (ETNA) Trial: A Randomized Phase 3 Clinical Trial

    Comparing Neoadjuvant Nab-paclitaxel vs Paclitaxel Both Followed by Anthracycline Regimens in Women With ERBB2/HER2-Negative Breast Cancer—The Evaluating Treatment With Neoadjuvant... द्वारा Gianni, Luca, Mansutti, Mauro, Anton, Antonio, Calvo, Lourdes, Bisagni, Giancarlo, Bermejo, Begoña, Semiglazov, Vladimir, Thill, Marc, Chacon, Jose Ignacio, Chan, Arlene, Morales, Serafin, Alvarez, Isabel, Plazaola, Arrate, Zambetti, Milvia, Redfern, Andrew D., Dittrich, Christian, Dent, Rebecca Alexandra, Magazzù, Domenico, De Fato, Raffaella, Valagussa, Pinuccia, Tusquets, Ignacio

    प्रकाशित 2018
    पूर्ण पाठ प्राप्त करें पूर्ण पाठ प्राप्त करें पूर्ण पाठ प्राप्त करें
    मूलपाठ
    सूची में सहेजें
    में बचाया:
  9. 9
    Safety, activity, and molecular heterogeneity following neoadjuvant non-pegylated liposomal doxorubicin, paclitaxel, trastuzumab, and pertuzumab in HER2-positive breast cancer (Opti-HER HEART): an open-label, single-group, multicenter, phase 2 trial

    Safety, activity, and molecular heterogeneity following neoadjuvant non-pegylated liposomal doxorubicin, paclitaxel, trastuzumab, and pertuzumab in HER2-positive breast cancer (Opt... द्वारा Gavilá, Joaquín, Oliveira, Mafalda, Pascual, Tomás, Perez-Garcia, Jose, Gonzàlez, Xavier, Canes, Jordi, Paré, Laia, Calvo, Isabel, Ciruelos, Eva, Muñoz, Montserrat, Virizuela, Juan A., Ruiz, Isabel, Andrés, Raquel, Perelló, Antonia, Martínez, Jerónimo, Morales, Serafín, Marín-Aguilera, Mercedes, Martínez, Débora, Quero, Juan C., Llombart-Cussac, Antonio, Prat, Aleix

    प्रकाशित 2019
    पूर्ण पाठ प्राप्त करें पूर्ण पाठ प्राप्त करें पूर्ण पाठ प्राप्त करें
    मूलपाठ
    सूची में सहेजें
    में बचाया:
  10. 10
    Derived Neutrophil-to-Lymphocyte Ratio Predicts Pathological Complete Response to Neoadjuvant Chemotherapy in Breast Cancer

    Derived Neutrophil-to-Lymphocyte Ratio Predicts Pathological Complete Response to Neoadjuvant Chemotherapy in Breast Cancer द्वारा Ocaña, Alberto, Chacón, Jose Ignacio, Calvo, Lourdes, Antón, Antonio, Mansutti, Mauro, Albanell, Joan, Martínez, María Teresa, Lahuerta, Ainhara, Bisagni, Giancarlo, Bermejo, Begoña, Semiglazov, Vladimir, Thill, Marc, Chan, Arlene, Morales, Serafin, Herranz, Jesús, Tusquets, Ignacio, Chiesa, Massimo, Caballero, Rosalía, Valagussa, Pinuccia, Bianchini, Giampaolo, Alba, Emilio, Gianni, Luca

    प्रकाशित 2022
    पूर्ण पाठ प्राप्त करें पूर्ण पाठ प्राप्त करें पूर्ण पाठ प्राप्त करें
    मूलपाठ
    सूची में सहेजें
    में बचाया:
  11. 11
    SOLTI NeoPARP: a phase II randomized study of two schedules of iniparib plus paclitaxel versus paclitaxel alone as neoadjuvant therapy in patients with triple-negative breast cancer

    SOLTI NeoPARP: a phase II randomized study of two schedules of iniparib plus paclitaxel versus paclitaxel alone as neoadjuvant therapy in patients with triple-negative breast cance... द्वारा Llombart-Cussac, Antonio, Bermejo, Begoña, Villanueva, Cristian, Delaloge, Suzette, Morales, Serafín, Balmaña, Judith, Amillano, Kepa, Bonnefoi, Hervé, Casas, Ana, Manso, Luis, Roché, Henri, Gonzalez-Santiago, Santiago, Gavilá, Joaquín, Sánchez-Rovira, Pedro, Di Cosimo, Serena, Harbeck, Nadia, Charpentier, Eric, Garcia-Ribas, Ignacio, Radosevic-Robin, Nina, Aura, Claudia, Baselga, Jose

    प्रकाशित 2015
    पूर्ण पाठ प्राप्त करें पूर्ण पाठ प्राप्त करें पूर्ण पाठ प्राप्त करें
    मूलपाठ
    सूची में सहेजें
    में बचाया:
  12. 12
    A phase Ib/II study of xentuzumab, an IGF-neutralising antibody, combined with exemestane and everolimus in hormone receptor-positive, HER2-negative locally advanced/metastatic breast cancer

    A phase Ib/II study of xentuzumab, an IGF-neutralising antibody, combined with exemestane and everolimus in hormone receptor-positive, HER2-negative locally advanced/metastatic bre... द्वारा Schmid, Peter, Sablin, Marie-Paule, Bergh, Jonas, Im, Seock-Ah, Lu, Yen-Shen, Martínez, Noelia, Neven, Patrick, Lee, Keun Seok, Morales, Serafín, Pérez-Fidalgo, J. Alejandro, Adamson, Douglas, Gonçalves, Anthony, Prat, Aleix, Jerusalem, Guy, Schlieker, Laura, Espadero, Rosa-Maria, Bogenrieder, Thomas, Huang, Dennis Chin-Lun, Crown, John, Cortés, Javier

    प्रकाशित 2021
    पूर्ण पाठ प्राप्त करें पूर्ण पाठ प्राप्त करें पूर्ण पाठ प्राप्त करें
    मूलपाठ
    सूची में सहेजें
    में बचाया:
  13. 13
    Immuno-priming durvalumab with bevacizumab in HER2-negative advanced breast cancer: a pilot clinical trial

    Immuno-priming durvalumab with bevacizumab in HER2-negative advanced breast cancer: a pilot clinical trial द्वारा Quintela-Fandino, Miguel, Holgado, Esther, Manso, Luis, Morales, Serafin, Bermejo, Begoña, Colomer, Ramon, Apala, Juan V., Blanco, Raquel, Muñoz, Manuel, Caleiras, Eduardo, Iranzo, Vega, Martinez, Mario, Dominguez, Orlando, Hornedo, Javier, Gonzalez-Cortijo, Lucia, Cortes, Javier, Gasol Cudos, Ariadna, Malon, Diego, Lopez-Alonso, Antonio, Moreno-Ortíz, María C., Mouron, Silvana, Mañes, Santos

    प्रकाशित 2020
    पूर्ण पाठ प्राप्त करें पूर्ण पाठ प्राप्त करें पूर्ण पाठ प्राप्त करें
    मूलपाठ
    सूची में सहेजें
    में बचाया:
  14. 14
    Broad consensus on the optimal sequence for the systemic treatment of metastatic breast cancer: results from a survey of Spanish medical oncologists

    Broad consensus on the optimal sequence for the systemic treatment of metastatic breast cancer: results from a survey of Spanish medical oncologists द्वारा Sánchez-Rovira, Pedro, Zamora, Pilar, Salvador-Bofill, Javier, Morales, Serafín, Martínez-Jáñez, Noelia, Martínez-de-Dueñas, Eduardo, Lluch, Ana, Illarramendi, José Juan, Gómez-Pardo, Patricia, Gavilá Gregori, Joaquín, García-Palomo, Andrés, García-Mata, Jesús, Fernández, Yolanda, del Barco, Sonia, de Juan, Ana, Ciruelos, Eva, Chacón, José Ignacio, Calvo, Lourdes, Barnadas, Agustí, Albanell, Joan

    प्रकाशित 2019
    पूर्ण पाठ प्राप्त करें पूर्ण पाठ प्राप्त करें पूर्ण पाठ प्राप्त करें
    मूलपाठ
    सूची में सहेजें
    में बचाया:
  15. 15
    A Pathology-Based Combined Model to Identify PAM50 Non-luminal Intrinsic Disease in Hormone Receptor-Positive HER2-Negative Breast Cancer

    A Pathology-Based Combined Model to Identify PAM50 Non-luminal Intrinsic Disease in Hormone Receptor-Positive HER2-Negative Breast Cancer द्वारा Pascual, Tomás, Martin, Miguel, Fernández-Martínez, Aranzazu, Paré, Laia, Alba, Emilio, Rodríguez-Lescure, Álvaro, Perrone, Giuseppe, Cortés, Javier, Morales, Serafín, Lluch, Ana, Urruticoechea, Ander, González-Farré, Blanca, Galván, Patricia, Jares, Pedro, Rodriguez, Adela, Chic, Nuria, Righi, Daniela, Cejalvo, Juan Miguel, Tonini, Giuseppe, Adamo, Barbara, Vidal, Maria, Villagrasa, Patricia, Muñoz, Montserrat, Prat, Aleix

    प्रकाशित 2019
    पूर्ण पाठ प्राप्त करें पूर्ण पाठ प्राप्त करें पूर्ण पाठ प्राप्त करें
    मूलपाठ
    सूची में सहेजें
    में बचाया:
  16. 16
    Pictilisib for oestrogen receptor-positive, aromatase inhibitor-resistant, advanced or metastatic breast cancer (FERGI): a randomised, double-blind, placebo-controlled, phase 2 trial

    Pictilisib for oestrogen receptor-positive, aromatase inhibitor-resistant, advanced or metastatic breast cancer (FERGI): a randomised, double-blind, placebo-controlled, phase 2 tri... द्वारा Krop, Ian E, Mayer, Ingrid A, Ganju, Vinod, Dickler, Maura, Johnston, Stephen, Morales, Serafin, Yardley, Denise A, Melichar, Bohuslav, Forero-Torres, Andres, Lee, Soo Chin, de Boer, Richard, Petrakova, Katarina, Vallentin, Susanne, Perez, Edith A, Piccart, Martine, Ellis, Matthew, Winer, Eric, Gendreau, Steven, Derynck, Mika, Lackner, Mark, Levy, Gallia, Qiu, Jiaheng, He, Jing, Schmid, Peter

    प्रकाशित 2016
    पूर्ण पाठ प्राप्त करें पूर्ण पाठ प्राप्त करें पूर्ण पाठ प्राप्त करें
    मूलपाठ
    सूची में सहेजें
    में बचाया:
  17. 17
    Phenotypic changes of HER2-positive breast cancer during and after dual HER2 blockade

    Phenotypic changes of HER2-positive breast cancer during and after dual HER2 blockade द्वारा Brasó-Maristany, Fara, Griguolo, Gaia, Pascual, Tomás, Paré, Laia, Nuciforo, Paolo, Llombart-Cussac, Antonio, Bermejo, Begoña, Oliveira, Mafalda, Morales, Serafín, Martínez, Noelia, Vidal, Maria, Adamo, Barbara, Martínez, Olga, Pernas, Sonia, López, Rafael, Muñoz, Montserrat, Chic, Núria, Galván, Patricia, Garau, Isabel, Manso, Luis, Alarcón, Jesús, Martínez, Eduardo, Gregorio, Sara, Gomis, Roger R., Villagrasa, Patricia, Cortés, Javier, Ciruelos, Eva, Prat, Aleix

    प्रकाशित 2020
    पूर्ण पाठ प्राप्त करें पूर्ण पाठ प्राप्त करें पूर्ण पाठ प्राप्त करें
    मूलपाठ
    सूची में सहेजें
    में बचाया:
  18. 18
    Limitations in predicting PAM50 intrinsic subtype and risk of relapse score with Ki67 in estrogen receptor-positive HER2-negative breast cancer

    Limitations in predicting PAM50 intrinsic subtype and risk of relapse score with Ki67 in estrogen receptor-positive HER2-negative breast cancer द्वारा Fernand ez-Martinez, Aranzazu, Pascual, Tomás, Perrone, Giuseppe, Morales, Serafin, de la Haba, Juan, González-Rivera, Milagros, Galván, Patricia, Zalfa, Francesca, Amato, Michela, Gonzalez, Lucia, Prats, Miquel, Rojo, Federico, Manso, Luis, Paré, Laia, Alonso, Immaculada, Albanell, Joan, Vivancos, Ana, González, Antonio, Matito, Judit, González, Sonia, Fernandez, Pedro, Adamo, Barbara, Muñoz, Montserrat, Viladot, Margarita, Font, Carme, Aya, Francisco, Vidal, Maria, Caballero, Rosalía, Carrasco, Eva, Altomare, Vittorio, Tonini, Giuseppe, Prat, Aleix, Martin, Miguel

    प्रकाशित 2017
    पूर्ण पाठ प्राप्त करें पूर्ण पाठ प्राप्त करें पूर्ण पाठ प्राप्त करें
    मूलपाठ
    सूची में सहेजें
    में बचाया:
  19. 19
    HER2-Enriched Subtype and ERBB2 Expression in HER2-Positive Breast Cancer Treated with Dual HER2 Blockade

    HER2-Enriched Subtype and ERBB2 Expression in HER2-Positive Breast Cancer Treated with Dual HER2 Blockade द्वारा Prat, Aleix, Pascual, Tomás, De Angelis, Carmine, Gutierrez, Carolina, Llombart-Cussac, Antonio, Wang, Tao, Cortés, Javier, Rexer, Brent, Paré, Laia, Forero, Andres, Wolff, Antonio C, Morales, Serafín, Adamo, Barbara, Brasó-Maristany, Fara, Vidal, Maria, Veeraraghavan, Jamunarani, Krop, Ian, Galván, Patricia, Pavlick, Anne C, Bermejo, Begoña, Izquierdo, Miguel, Rodrik-Outmezguine, Vanessa, Reis-Filho, Jorge S, Hilsenbeck, Susan G, Oliveira, Mafalda, Dieci, Maria Vittoria, Griguolo, Gaia, Fasani, Roberta, Nuciforo, Paolo, Parker, Joel S, Conte, PierFranco, Schiff, Rachel, Guarneri, Valentina, Osborne, C Kent, Rimawi, Mothaffar F

    प्रकाशित 2019
    पूर्ण पाठ प्राप्त करें पूर्ण पाठ प्राप्त करें पूर्ण पाठ प्राप्त करें
    मूलपाठ
    सूची में सहेजें
    में बचाया:
  20. 20
    Palbociclib combined with endocrine therapy in heavily pretreated HR(+)/HER2(-) advanced breast cancer patients: Results from the compassionate use program in Spain (PALBOCOMP)

    Palbociclib combined with endocrine therapy in heavily pretreated HR(+)/HER2(-) advanced breast cancer patients: Results from the compassionate use program in Spain (PALBOCOMP) द्वारा Manso, Luis, Hernando, Cristina, Galán, María, Oliveira, Mafalda, Cabrera, Miguel A., Bratos, Raquel, Rodríguez, César A., Ruiz-Borrego, Manuel, Blanch, Salvador, Llombart-Cussac, Antonio, Delgado-Mingorance, Juan I., Álvarez-Busto, Iñaki, Gallegos, Isabel, González-Cortijo, Lucía, Morales, Serafín, Aguirre, Elena, Hernando, Blanca A., Ballesteros, Ana, Alés-Martínez, José E., Reboredo, Cristina, Oltra, Amparo, González-Cao, María, Santisteban, Marta, Malón, Diego, Echeverría, Isabel, García-Garre, Elisa, Vega, Estela, Servitja, Sònia, Andrés, Raquel, Robles, Carlos E., López, Rafael, Galve, Elena, Echarri, María J., Legeren, Marta, Moreno, Fernando

    प्रकाशित 2020
    पूर्ण पाठ प्राप्त करें पूर्ण पाठ प्राप्त करें पूर्ण पाठ प्राप्त करें
    मूलपाठ
    सूची में सहेजें
    में बचाया:

खोज साधन: